PepGenPEPG
Market Cap: $305M
About: PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Employees: 72
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
71% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 14
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
10% more capital invested
Capital invested by funds: $363M [Q1] → $401M (+$38M) [Q2]
9% more funds holding
Funds holding: 56 [Q1] → 61 (+5) [Q2]
1.17% more ownership
Funds ownership: 76.4% [Q1] → 77.57% (+1.17%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Andrew Fein 46% 1-year accuracy 76 / 167 met price target | 178%upside $26 | Buy Reiterated | 1 Aug 2024 |
Wedbush Laura Chico 48% 1-year accuracy 33 / 69 met price target | 114%upside $20 | Outperform Reiterated | 31 Jul 2024 |
Financial journalist opinion
Based on 30 articles about PEPG published over the past 30 days